EGFR and non-small cell lung carcinoma: Patritumab deruxtecan was granted a Breakthrough Therapy Designation in 2021 and Priority Review to the Biologics License Application (BLA) in 2023 and awaits its FDA approval as a third-line treatment for patients with EGFR-mutated NSCLC [196,197].